Limbal Stem Cell Deficiency (LSCD)
3
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Amniotic Membrane Extract Eye Drop Ameed
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The Improvement of Limbal Stem Cell Deficiency (LSCD) in Unilateral Stem Cell Damage by Amniotic Membrane Extract Eye Drop (AMEED)
Research Network
Common Treatments
- Amniotic Membrane Extract Eye Drop Ameed1
- Brm421 Ophthalmic Solution 0061
Active Sponsors
- IRCCS San Raffaele1
- BRIM Biotechnology Inc.1
- Royan Institute1
- University of Pennsylvania1
Top Investigators
Labafi Nejad Eye Research Center, Tehran, Iran
head of Royan Institute
Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Department of Regenerative Biomedicine at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Related Conditions
- Cornea Abnormality1
- Cornea Disease1
- Cornea Inflamed1
- Exposure Keratopathy1
- Neurotrophic Keratopathy1